• Moderna flagged three ESMO Congress 2026 presentations on intismeran autogene, an individualized mRNA neoantigen therapy developed with Merck.
• Late-breaking Phase 3 melanoma data are scheduled for Oct. 24, 2026, signaling an upcoming readout for a pivotal adjuvant program.
• Earlier-stage updates in pancreatic cancer and early-stage NSCLC are also slated for poster sessions, extending the product’s potential across multiple tumors.
• Results have not yet been presented; disclosures are planned for Oct. 23-27, 2026, in Madrid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609211012ACCESSWRNAPR_____1224628) on September 21, 2026, and is solely responsible for the information contained therein.